Horvath, Noemi
Spencer, Andrew
Kenealy, Melita
Joshua, Douglas
Campbell, Philip J
Lee, Je-Jung
Hou, Jian
Qiu, Lugui
Kalff, Anna
Khong, Tiffany
Londhe, Anil
Siggins, Sarah
van Kooten Losio, Maximiliano
Eisbacher, Michael
Prince, H. Miles
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study
https://doi.org/10.1080/10428194.2019.1579322
Funding for this research was provided by:
Janssen Global Services, LLC
Millennium Pharmaceuticals, Inc.
a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Janssen Pharmaceutical NV
Janssen Pharmaceutical
Janssen and Celgene
Peer Review Statement: The publishing and review policy for this title is described in its Aims & Scope.
Publication History
Received: 2018-09-12
Revised: 2019-01-24
Accepted: 2019-01-28
Published: 2019-02-19